At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
RAD001drug
Likely dose
RAD001 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm, Two Center, Phase II Study of RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating RAD001 for Hormone Refractory Prostate Cancer. Completed, enrolled 35 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the biochemical response rate (PSA) to single agent RAD001 in patients with metastatic hormone-refractory prostate cancer (HRPC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHormone Refractory Prostate Cancer
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2005
First PostedMar 2008
Primary CompletionDec 2009
Study CompletionJan 2010
TodayJul 2026
First PostedMar 6, 2008
Enrollment StartAug 1, 2005
Primary CompletionDec 1, 2009
Study CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 18.3 years ago
Interventions
RAD001drug
RAD001 at a dose of 10 mg PO daily